From the publishers of JADPRO
Biomarkers in NSCLC
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Advertisement
Fast Facts #1: The Importance of Driver Mutations in NSCLC
Last Updated: Monday, January 25, 2021
Advertisement
News & Literature Highlights
Journal of Thoracic Oncology
Biomarker Discovery and Validation: Statistical Considerations
Lung Cancer
Biomarker Testing in Non-Small Cell Lung Cancer in Routine Care: Analysis of the First 3,717 Patients in the German Prospective, Observational, Nation-Wide CRISP Registry (AIO-TRK-0315)
Journal of Clinical Oncology
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
European Journal of Cancer
COVID-19 in Lung Cancer Patients Receiving ALK/ROS1 Inhibitors
Translational Lung Cancer Research
Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer
Translational Lung Cancer Research
Neoadjuvant Treatment of Stage IIIA-N2 in EGFR-Mutant/ALK-Rearranged Non–Small Cell Lung Cancer
New England Journal of Medicine
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
The ASCO Post
FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations
International Association for the Study of Lung Cancer
Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of US-Based Oncology Clinicians
Frontiers in Oncology
A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors
Advertisement
Fast Facts
Fast Facts #12: Choosing/Sequencing Therapy
Advertisement
Quizzes
Test your knowledge on pathways and targets
Test your knowledge on targeted therapies for MET/RET
Test your knowledge on Targeted Therapies for EGFR/ALK/ROS1